Home > Boards > US Listed > Biotechs > Portola Phramaceuticals (PTLA)

Feb 28 coming up!

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
H2R Member Profile
 
Followed By 14
Posts 1,459
Boards Moderated 0
Alias Born 07/17/14
160x600 placeholder
Portola Pharmaceuticals to Announce Third Quarter 2019 Financial Results on Tuesday, November 5, 2019 PR Newswire (US) - 10/15/2019 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/2/2019 4:21:37 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 10/2/2019 4:17:31 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/23/2019 6:33:32 AM
Portola Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors PR Newswire (US) - 9/19/2019 8:20:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/5/2019 7:06:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/5/2019 7:03:49 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/3/2019 6:05:36 PM
Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences PR Newswire (US) - 8/22/2019 8:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/14/2019 4:20:36 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 8/14/2019 4:15:44 PM
Portola Pharmaceuticals Announces Pricing of Public Offering of Common Stock PR Newswire (US) - 8/13/2019 7:32:00 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 8/12/2019 4:46:55 PM
Portola Pharmaceuticals Announces Proposed Offering of Common Stock PR Newswire (US) - 8/12/2019 4:43:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/9/2019 6:51:55 PM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 8/7/2019 5:16:00 PM
Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr) Edgar (US Regulatory) - 8/7/2019 5:12:36 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/7/2019 4:32:57 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/7/2019 4:13:13 PM
Portola Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update PR Newswire (US) - 8/7/2019 4:05:00 PM
Portola Launches European Sales of Ondexxya® (Andexanet Alfa) with First Orders in Europe PR Newswire (US) - 8/6/2019 8:30:00 AM
U.S. Centers for Medicare and Medicaid Services (CMS) Increases New Technology Add-On Payment (NTAP) Reimbursement for Portol... PR Newswire (US) - 8/5/2019 7:00:00 AM
Portola Pharmaceuticals to Announce Second Quarter 2019 Financial Results on Wednesday, August 7, 2019 PR Newswire (US) - 7/17/2019 8:30:00 AM
Portola Pharmaceuticals Presents New In Vitro Data Demonstrating that Four-Factor Prothrombin Complex Concentrates (4F-PCCs) ... PR Newswire (US) - 7/8/2019 8:30:00 AM
Portola Presents New Interim Data on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Re... PR Newswire (US) - 6/19/2019 11:05:00 AM
H2R   Saturday, 02/23/19 04:41:00 PM
Re: None
Post # of 182 
Feb 28 coming up!

investors.portola.com/phoenix.zhtml?c=198136&p=irol-newsroomArticle&ID=2380212

Quote:
CHMP Extends Review Period for Portola Pharmaceuticals’ Ondexxya™ (andexanet alfa)
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has extended the review period for the Company’s marketing authorization application (MAA) for Ondexxya™ (andexanet alfa), and cancelled the Oral Explanation scheduled for Wednesday, December 12, 2018. An opinion is now expected by February 28, 2019.



Best of luck with your investments!

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist